J Adv Prosthodont.  2014 Dec;6(6):505-511. 10.4047/jap.2014.6.6.505.

The influence of systemically administered oxytocin on the implant-bone interface area: an experimental study in the rabbit

• Cho SA
• Park SH
• Cho JH

• KMID: 2284725
• DOI: http://doi.org/10.4047/jap.2014.6.6.505

Abstract

PURPOSE
The purpose of this study was to assess the effect of systemically administered oxytocin (OT) on the implant-bone interface by using histomorphometric analysis and the removal torque test.
MATERIALS AND METHODS
A total of 10 adult, New Zealand white, female rabbits were used in this experiment. We placed 2 implants (CSM; CSM Implant, Daegu, South Korea) in each distal femoral metaphysis on both the right and left sides; the implants on both sides were placed 10 mm apart. In each rabbit, 1 implant was prepared for histomorphometric analysis and the other 3 were prepared for the removal torque test (RT). The animals received intramuscular injections of either saline (control group; 0.15 M NaCl) or OT (experimental group; 200 microg/rabbit). The injections were initiated on Day 3 following the implant surgery and were continued for 4 subsequent weeks; the injections were administered twice per day (at a 12-h interval), for 2 days per week.
RESULTS
While no statistically significant difference was observed between the two groups (P=.787), the control group had stronger removal torque values. The serum OT concentration (ELISA value) was higher in the OT-treated group, although no statistically significant difference was found. Further, the histomorphometric parameter (bone-toimplant contact [BIC], inter-thread bone, and peri-implant bone) values were higher in the experimental group, but the differences were not significant.
CONCLUSION
We postulate that OT supplementation via intramuscular injection weakly contributes to the bone response at the implant-bone interface in rabbits. Therefore, higher concentrations or more frequent administration of OT may be required for a greater bone response to the implant. Further studies analyzing these aspects are needed.

Keyword

Oxytocin; Removal torque test; Histomorphometric parameter; Dental implant

MeSH Terms

Adult
Animals
Daegu
Dental Implants
Female
Humans
Injections, Intramuscular
New Zealand
Oxytocin*
Rabbits
Torque
Dental Implants
Oxytocin

Figure

• 

  Fig. 1 Intramuscular injections (oxytocin or saline) were given 2 times/2 days/week and animals were sacrificed at 31 days after surgery.

• 

  Fig. 2 An MGT-12 digital torque gauge (Mark-10 Corp, New York, NY, USA) was used to measure the removal torque with a connector specifically made to connect the torque gauge and the fixture.

• 

  Fig. 3 The inter-thread bone density was defined as the area of bone inside the 4 most-central threads (×100%). The percentage of peri-implant bone area was defined as the area of bone that had formed after implant insertion/rectangular area (×100%) (1 mm × 1.2 mm rectangle; 2 rectangles per implant). The bone-to-implant contact (BIC) was determined by linear measurement of direct bone contact with the implant surface.

• 

  Fig. 4 Mean values of the removal torque force for the control and experimental groups. No statistically significant difference was observed between the two groups (P=.787), although the control group showed higher values.

• 

  Fig. 5 Oxytocin concentrations (pg/mL) were calculated from the standard curve. The mean value for the experimental group was 936.81 pg/mL and that of the control group was 705.89 pg/mL; the values were not significantly different.

• 

  Fig. 6 Representative images at 31 days after dental implantation in an oxytocin (OT)-treated and a control sample with new bone formation between all threads. The histomorphometric cross-sectional view of an implant in an OT-treated sample (A) corresponding to the peri-implant bone area in which it was observed shows a similar percentage of bone tissue in contact with the implant when compared with similar sections in a control sample (B).

Reference

1. Adell R, Lekholm U, Rockler B, Brånemark PI. A 15-year study of osseointegrated implants in the treatment of the edentulous jaw. Int J Oral Surg. 1981; 10:387–416.

2. Cochran DL, Morton D, Weber HP. Consensus statements and recommended clinical procedures regarding loading protocols for endosseous dental implants. Int J Oral Maxillofac Implants. 2004; 19:109–113.

3. Le Guéhennec L, Soueidan A, Layrolle P, Amouriq Y. Surface treatments of titanium dental implants for rapid osseointegration. Dent Mater. 2007; 23:844–854.

4. Sykaras N, Woody RD, Lacopino AM, Triplett RG, Nunn ME. Osseointegration of dental implants complexed with rh-BMP-2: a comparative histomorphometric and radiographic evaluation. Int J Oral Maxillofac Implants. 2004; 19:667–678.

5. Blom EJ, Verheij JG, de Blieck-Hogervorst JM, Di Silvio L, Klein CP. Cortical bone ingrowth in growth hormone-loaded grooved implants with calcium phosphate coatings in goat femurs. Biomaterials. 1998; 19:263–270.

6. Stenport VF, Olsson B, Morberg P, Törnell J, Johansson CB. Systemically administered human growth hormone improves initial implant stability: an experimental study in the rabbit. Clin Implant Dent Relat Res. 2001; 3:135–141.

7. Tresguerres IF, Clemente C, Donado M, Gómez-Pellico L, Blanco L, Alobera MA, Tresguerres JA. Local administration of growth hormone enhances periimplant bone reaction in an osteoporotic rabbit model. Clin Oral Implants Res. 2002; 13:631–636.

8. Park JW, Kim JM, Lee HJ, Jeong SH, Suh JY, Hanawa T. Bone healing with oxytocin-loaded microporous β-TCP bone substitute in ectopic bone formation model and critical-sized osseous defect of rat. J Clin Periodontol. 2014; 41:181–190.

9. Tamma R, Colaianni G, Zhu LL, DiBenedetto A, Greco G, Montemurro G, Patano N, Strippoli M, Vergari R, Mancini L, Colucci S, Grano M, Faccio R, Liu X, Li J, Usmani S, Bachar M, Bab I, Nishimori K, Young LJ, Buettner C, Iqbal J, Sun L, Zaidi M, Zallone A. Oxytocin is an anabolic bone hormone. Proc Natl Acad Sci USA. 2009; 106:7149–7154.

10. Colaianni G, Di Benedetto A, Zhu LL, Tamma R, Li J, Greco G, Peng Y, Dell›Endice S, Zhu G, Cuscito C, Grano M, Colucci S, Iqbal J, Yuen T, Sun L, Zaidi M, Zallone A. Regulated production of the pituitary hormone oxytocin from murine and human osteoblasts. Biochem Biophys Res Commun. 2011; 411:512–515.

11. Colli VC, Okamoto R, Spritzer PM, Dornelles RC. Oxytocin promotes bone formation during the alveolar healing process in old acyclic female rats. Arch Oral Biol. 2012; 57:1290–1297.

12. Amar AP, Weiss MH. Pituitary anatomy and physiology. Neurosurg Clin N Am. 2003; 14:11–23.

13. Lee HJ, Macbeth AH, Pagani JH, Young WS 3rd. Oxytocin: the great facilitator of life. Prog Neurobiol. 2009; 88:127–151.

14. Colaianni G, Tamma R, Di Benedetto A, Yuen T, Sun L, Zaidi M, Zallone A. The oxytocin-bone axis. J Neuroendocrinol. 2014; 26:53–57.

15. Breuil V, Amri EZ, Panaia-Ferrari P, Testa J, Elabd C, Albert-Sabonnadière C, Roux CH, Ailhaud G, Dani C, Carle GF, Euller-Ziegler L. Oxytocin and bone remodelling: relationships with neuropituitary hormones, bone status and body composition. Joint Bone Spine. 2011; 78:611–615.

16. Petersson M, Lagumdzija A, Stark A, Bucht E. Oxytocin stimulates proliferation of human osteoblast-like cells. Peptides. 2002; 23:1121–1126.

17. Luo T, Zhang W, Shi B, Cheng X, Zhang Y. Enhanced bone regeneration around dental implant with bone morphogenetic protein 2 gene and vascular endothelial growth factor protein delivery. Clin Oral Implants Res. 2012; 23:467–473.

18. Gómez-Moreno G, Cutando A, Arana C, Worf CV, Guardia J, Muñoz F, Lopez-Peña M, Stephenson J. The effects of growth hormone on the initial bone formation around implants. Int J Oral Maxillofac Implants. 2009; 24:1068–1073.

19. Liu X, Shimono K, Zhu LL, Li J, Peng Y, Imam A, Iqbal J, Moonga S, Colaianni G, Su C, Lu Z, Iwamoto M, Pacifici M, Zallone A, Sun L, Zaidi M. Oxytocin deficiency impairs maternal skeletal remodeling. Biochem Biophys Res Commun. 2009; 388:161–166.

20. MacDonald E, Dadds MR, Brennan JL, Williams K, Levy F, Cauchi AJ. A review of safety, side-effects and subjective reactions to intranasal oxytocin in human research. Psychoneuroendocrinology. 2011; 36:1114–1126.

21. Işeri SO, Sener G, Saglam B, Gedik N, Ercan F, Yegen BC. Oxytocin protects against sepsis-induced multiple organ damage: role of neutrophils. J Surg Res. 2005; 126:73–81.

22. Petersson M, Lagumdzija A, Stark A, Bucht E. Oxytocin stimulates proliferation of human osteoblast-like cells. Peptides. 2002; 23:1121–1126.

23. Rydén G, Sjöholm I. Half-life of oxytocin in blood of pregnant and non-pregnant women. Acta Endocrinol (Copenh). 1969; 61:425–431.